Ramli, Fitri Fareez
Singh, Nisha
Emir, Uzay E.
Villa, Luca M.
Waters, Shona
Harmer, Catherine J. http://orcid.org/0000-0002-1609-8335
Cowen, Philip J. http://orcid.org/0000-0001-5518-6138
Godlewska, Beata R. http://orcid.org/0000-0002-5973-3765
Funding for this research was provided by:
RCUK | Medical Research Council (MR/K022202, MR/K022202)
Sound Pharmaceuticals and the NIHR Oxford Health Biomedical Research Centre.
Universiti Kebangsaan Malaysia
Yayasan Khazanah
Article History
Received: 27 January 2024
Revised: 30 March 2024
Accepted: 3 April 2024
First Online: 7 May 2024
Competing interests
: PJC holds a patent on behalf of Oxford University for the use of ebselen in patients with resistant depression. CJH was supported by the NIHR Oxford Health Biomedical Research Centre; she has received consultancy fees from P1vital, Lundbeck, Servier, UCB, Zogenix, J&J, IESO outside of the current work. BRG, FFR, NS, UEE, SW and LMV declare no competing interests.
: The study was approved by the National Research Ethics Service Committee (NRES), South-Central Oxford (ID:20/SC/0151).
: Informed consent was obtained from all participants before the study.